All Blogs

Mar 11, 2022

Peripheral nerve injuries were historically became known to mankind on the battlefield during Second World War. With technological advancements over the years, peripheral nerve injuries (PNI) have become more common which can be attributed to various reasons such as traumatic injuries, gunshot wounds, rising preval...

Mar 10, 2022

Bioventus Receives 501(k) Clearance for StimRouter Pain Management Device On March 1, 2022, the US Food and Drug Administration (FDA) gave Bioventus' StimRouter Neuromodulation System 510(k) approval. The next-generation pain treatment device is intended to treat chronic pain caused by peripheral nerves, ex...

Nov 04, 2025

Introduction With a growing number of people affected by osteoporosis and other bone-related conditions worldwide, there is an increasing need for accurate and accessible tools to check bone health. One of the most important devices used today is the bone densitometer, which measures bone mineral density (BMD), ...

Mar 08, 2022

Eli Lilly, Boehringer Ingelheim’s Jardiance Giving Competition to AstraZeneca’s Farxiga with EU Approval Jardiance, the diabetes blockbuster from Eli Lilly and Boehringer Ingelheim, recently received a Heart Failure label expansion in the United States. Now, the drug is expanding into Europe, with a nod that mig...

Mar 07, 2022

Cancer diagnostics is an umbrella term that encompasses all diagnostics modalities such as imaging, molecular diagnostics, and biopsy employed in drawing conclusions regarding cancer diagnosis and devising prognostic strategies.  Liquid Biopsy is comparatively a new technique in the cancer diagnosis and the...

Sep 24, 2024

Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s disease is a rare, progressive, and fatal neuromuscular disease characterized by degeneration of upper and lower motor neurons. While it is associated with a mortality rate of 50% within 30 months of Amyotrophic Lateral Sclerosis symptoms onset, there is still no ...

Mar 03, 2022

Enhertu with Opdivo exhibited clinical efficacy with an ORR of 36.7% in HER2+ urothelial cancer in Phase Ib study On the second day of ASCO-GU 2022, the rapid abstract session highlighted the results from the DS8201-A-U105 trial (NCT03523572; Active, not recruiting) of Enhertu (trastuzumab deruxtecan) with Opdiv...

Mar 03, 2022

Noninvasix Granted the US FDA Breakthrough Device Designation for Non-Invasive Monitoring Technology for Sepsis On February 23, 2022, Noninvasix, Inc. received the US FDA breakthrough device designation for its LIVOx™ Central Venous Oxygenation Monitor. It is a non-invasive device and provides real-time, ...

Aug 27, 2025

Medication management apps have become essential digital tools for helping individuals stay on top of their medication routines. These apps are designed to enhance adherence by providing timely reminders and alerts, ensuring that medications are taken at the right time and in the correct dosage. They also offer fea...

Mar 02, 2022

Chemotherapy, immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates are being used for treating Urothelial Carcinoma(UC) patients and now PARP inhibitors are being studied in UC in the neoadjuvant, first-line, maintenance therapy, and subsequent lines of the setting. It is worth n...